- Home
- BLRX vs MIRA Comparison
BLRX vs MIRA Comparison
Compare BLRX & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- MIRA
- Stock Information
- Founded
- BLRX 2003
- MIRA 2020
- Country
- BLRX Israel
- MIRA United States
- Employees
- BLRX N/A
- MIRA N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- MIRA Health Care
- Exchange
- BLRX Nasdaq
- MIRA Nasdaq
- Market Cap
- BLRX 17.0M
- MIRA 19.5M
- IPO Year
- BLRX 2011
- MIRA 2023
- Fundamental
- Price
- BLRX $4.25
- MIRA $1.73
- Analyst Decision
- BLRX Strong Buy
- MIRA Strong Buy
- Analyst Count
- BLRX 2
- MIRA 2
- Target Price
- BLRX $19.00
- MIRA $14.00
- AVG Volume (30 Days)
- BLRX 36.3K
- MIRA 3.6M
- Earning Date
- BLRX 08-14-2025
- MIRA 08-12-2025
- Dividend Yield
- BLRX N/A
- MIRA N/A
- EPS Growth
- BLRX N/A
- MIRA N/A
- EPS
- BLRX N/A
- MIRA N/A
- Revenue
- BLRX $22,340,000.00
- MIRA N/A
- Revenue This Year
- BLRX N/A
- MIRA N/A
- Revenue Next Year
- BLRX N/A
- MIRA N/A
- P/E Ratio
- BLRX N/A
- MIRA N/A
- Revenue Growth
- BLRX 91.68
- MIRA N/A
- 52 Week Low
- BLRX $2.30
- MIRA $0.73
- 52 Week High
- BLRX $35.60
- MIRA $3.73
- Technical
- Relative Strength Index (RSI)
- BLRX 43.97
- MIRA 60.96
- Support Level
- BLRX $4.47
- MIRA $1.61
- Resistance Level
- BLRX $4.75
- MIRA $2.09
- Average True Range (ATR)
- BLRX 0.30
- MIRA 0.19
- MACD
- BLRX -0.04
- MIRA 0.03
- Stochastic Oscillator
- BLRX 11.96
- MIRA 64.71
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.